| Literature DB >> 34950433 |
Jie Li1, Xiao-Ming Chen2, Chun-Ze Zhou1, Wei-Wei Fang3, Wei-Fu Lv1, De-Lei Cheng4.
Abstract
BACKGROUND: Budd-Chiari syndrome (BCS) is an uncommon disorder characterized by obstruction of hepatic venous outflow. To date, the exact mechanism underlying hepatic injury derived from the hepatic venous outflow obstruction in BCS remains largely unknown. AIM: To assess the role of NF-κB-mediated inflammation in BCS-induced liver injury in humans and rats.Entities:
Keywords: Budd-Chiari syndrome; Lipopolysaccharide; Liver injury; Nuclear factor-kappa B; Toll-like receptor 4
Year: 2021 PMID: 34950433 PMCID: PMC8649562 DOI: 10.4240/wjgs.v13.i11.1448
Source DB: PubMed Journal: World J Gastrointest Surg
Primers used in this study
|
|
|
|
| β-actin (150 bp) | 5’-CCCATCTATGAGGGTTACGC-3’ | 5’-TTTAATGTCACGCACGATTTC-3’ |
| TLR4 (186 bp) | 5’-GCCGGAAAGTTATTGTGGTGGT-3’ | 5’-ATGGGTTTTAGGCGCAGAGTTT-3’ |
| NF-κB p65 (108 bp) | 5’-AAGATCTGCCGAGTAAACCG-3 | 5’-TCCCGTGAAATACACCTCAA-3’ |
| IL-2 (113 bp) | 5’-CAAGCAGGCCACAGAATTGA-3’ | 5’-TTCCAGCGTCTTCCAAGTGA-3’ |
| TNF-α (89 bp) | 5’-AGGAGGGAGAACAGCAACTC-3’ | 5’-TGTATGAGAGGGACGGAACC-3’ |
| IFN-γ (130 bp) | 5’-CAGGCCATCAGCAACAACAT-3’ | 5’-GCTGGATCTGTGGGTTGTTC-3’ |
TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ.
Figure 1Digital subtraction angiography images and hematoxylin-eosin staining images in the rat model of Budd-Chiari syndrome. A: A1: Control group; A2: The sham operation group. Two groups showed that the inferior vena cava (IVC) blood flow was smooth, but no stenosis or occlusion of the IVC and hepatic vein (HV) (black arrow); A3: In the 1 model group 1W, IVC stenosis above the opening of the HV could be seen, and the contrast agent passed through in a line, without obvious collateral vessel formation (black arrow); A4: In the model group 3W, a small amount of collateral vessel formation around the IVC (black arrow); A5: In the model group 6W, a large number of collateral vessels around the IVC (black arrow); A6: In the model group 12W, the collateral vessels around the IVC were further increased and thickened (black arrow); B: B1: Control group; B2-B5: Four groups of sham operation group, 1W (B2), 3W (B3), 6W (B4) and 12W (B5). Hepatocytes were arranged in a single row radially centered on the central vein, with no change in hepatocytes and hepatic sinusoids (B1–B5); B6: Model group 1W. Hyaline degeneration of rat hepatocytes and no obvious dilation and stagnation of red blood cells in hepatic sinusoids (black arrow); B7: Model group 3W. The hyaline degeneration of rat hepatocytes was aggravated, the hepatocytes around the central vein were necrotic, and the hepatic sinusoids were dilated with a small amount of stasis red blood cells (black arrow); B8: Model group 6W. Large sheet necrosis of liver cells around the central vein, further expansion of liver sinusoids, more stasis of red blood cells in the expanded liver sinusoids (black arrow); B9: Model group 12W. The arrangement of liver cells was disordered, the normal hepatocyte cord disappeared, the hepatic sinusoids were significantly expanded and there was a large number of erythrocytes (black arrow). Original magnification × 200. Bar = 50 μm.
Figure 2Hepatic mRNA and protein expression levels of lipopolysaccharide and various factors in rats and humans. A: The expression levels of lipopolysaccharide (LPS) in each group; B: TLR4 expression in each group; C: Nuclear factor-kappa B p65 expression in each group; D: Tumor necrosis factor-α expression in each group; E: Interferon-γ expression in each group; F: Interleukin-2 expression in each group; G: Western blot analysis of protein express levels of various factors in the rat liver tissues; H: Levels of LPS and TLR4/NF-κB mediated inflammation-related indicators in the blood samples from human subjects. LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-kappa B; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ. aP < 0.05 comparisons between subgroups. bP < 0.05 comparisons between model subgroups.
mRNA expression levels of TLR4/NF-κB-mediated inflammation-related indicators
|
|
|
|
|
|
|
| Control group | 1.004 ± 0.139 | 1.003 ± 0.074 | 1.001 ± 0.121 | 1.001 ± 0.126 | 1.005 ± 0.101 |
| Sham-operated group | |||||
| 1W | 1.101 ± 0.127 | 1.101 ± 0.127 | 1.108 ± 0.206 | 1.068 ± 0.222 | 1.102 ± 0.121 |
| 3W | 1.013 ± 0.109 | 1.013 ± 0.109 | 1.061 ± 0.168 | 1.042 ± 0.181 | 1.082 ± 0.111 |
| 6W | 1.045 ± 0.118 | 1.045 ± 0.118 | 1.006 ± 0.141 | 1.047 ± 0.164 | 1.004 ± 0.084 |
| 12W | 1.059 ± 0.115 | 1.059 ± 0.115 | 1.025 ± 0.097 | 1.017 ± 0.157 | 1.019 ± 0.118 |
| Model group | |||||
| 1W | 1.773 ± 0.165 | 1.773 ± 0.165 | 1.935 ± 0.217 | 1.991 ± 0.181 | 2.170 ± 0.195 |
| 3W | 6.789 ± 0.692 | 6.789 ± 0.692 | 6.144 ± 0.681 | 12.931 ± 1.424 | 9.172 ± 0.902 |
| 6W | 4.671 ± 0.593 | 4.671 ± 0.593 | 4.372 ± 0.268 | 7.629 ± 0.999 | 5.131 ± 0.441 |
| 12W | 1.003 ± 0.074 | 3.575 ± 0.334 | 3.011 ± 0.326 | 3.991 ± 0.391 | 2.855 ± 0.732 |
| Statistics | 333.288 | 464.025 | 426.396 | 555.318 | 509.268 |
|
| < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 |
P < 0.05, comparisons between subgroups, the differences are statistically significant.
P < 0.05, comparisons between model subgroups, the differences are statistically significant.
TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ.
Relative protein expression levels of TLR4/NF-κB-mediated inflammation-related indicators
|
|
|
|
|
|
|
| Control group | 0.555 ± 0.066 | 0.317 ± 0.022 | 0.232 ± 0.029 | 0.368 ± 0.032 | 0.369 ± 0.023 |
| Sham-operated group | |||||
| 1W | 0.561 ± 0.059 | 0.327 ± 0.019 | 0.229 ± 0.028 | 0.366 ± 0.026 | 0.379 ± 0.029 |
| 3W | 0.560 ± 0.068 | 0.313 ± 0.023 | 0.242 ± 0.029 | 0.357 ± 0.022 | 0.359 ± 0.026 |
| 6W | 0.561 ± 0.071 | 0.310 ± 0.030 | 0.236 ± 0.027 | 0.369 ± 0.034 | 0.362 ± 0.020 |
| 12W | 0.564 ± 0.070 | 0.309 ± 0.025 | 0.234 ± 0.027 | 0.371 ± 0.028 | 0.377 ± 0.028 |
| Model group | |||||
| 1W | 0.729 ± 0.067 | 0.678 ± 0.058 | 0.449 ± 0.057 | 0.684 ± 0.024 | 0.700 ± 0.082 |
| 3W | 1.507 ± 0.086 | 1.416 ± 0.087 | 1.047 ± 0.058 | 1.188± 0.051 | 1.261 ± 0.073 |
| 6W | 1.162 ± 0.070 | 1.192 ± 0.079 | 0.848 ± 0.056 | 1.050 ± 0.043 | 1.069 ± 0.090 |
| 12W | 1.001 ± 0.072 | 0.880 ± 0.090 | 0.610 ± 0.059 | 0.835 ± 0.065 | 0.845 ± 0.063 |
| Statistics | 291.836 | 711.802 | 608.214 | 897.062 | 488.525 |
|
| < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 | < 0.0001 |
P < 0.05, comparisons between subgroups, the differences are statistically significant.
P < 0.05, comparisons between model subgroups, the differences are statistically significant.
TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ.
Correlation between lipopolysaccharide and mRNA levels of various inflammation-related indicators
|
|
|
|
|
|
|
|
| LPS | 1 | 0.959 | 0.945 | 0.939 | 0.942 | 0.944 |
| NF-κBp65 | 0.945 | 0.930 | 1 | 0.941 | 0.954 | 0.966 |
| IL-2 | 0.939 | 0.952 | 0.941 | 1 | 0.982 | 0.946 |
| TNF-α | 0.942 | 0.953 | 0.954 | 0.982 | 1 | 0.954 |
| IFN-γ | 0.944 | 0.932 | 0.966 | 0.946 | 0.954 | 1 |
P < 0.01.
LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ.
Correlation between lipopolysaccharide and protein expression of inflammation-related indicators
|
|
|
|
|
|
|
|
| LPS | 1 | 0.954 | 0.929 | 0.931 | 0.930 | 0.936 |
| TLR4 | 0.954 | 1 | 0.915 | 0.900 | 0.930 | 0.910 |
| NF-κBp65 | 0.929 | 0.915 | 1 | 0.954 | 0.949 | 0.961 |
| IFN-γ | 0.931 | 0.900 | 0.954 | 1 | 0.938 | 0.957 |
| TNF-α | 0.930 | 0.930 | 0.949 | 0.938 | 1 | 0.954 |
| IL-2 | 0.936 | 0.910 | 0.961 | 0.957 | 0.954 | 1 |
P < 0.01.
LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ.
Figure 3Scatter diagram of lipopolysaccharide and nuclear factor-κB-mediated inflammation-related factors. A: mRNA level; B: Protein level. LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ.
Levels of lipopolysaccharide and TLR4/NF-κB-mediated inflammation-related indicators in the blood samples from human subjects
|
|
|
|
|
|
|
|
| Control group | 8.42 ± 2.33 | 5.05 ± 1.29 | 8.15 ± 1.65 | 21.19 ± 5.01 | 24.88 ± 4.07 | 16.60 ± 1.80 |
| Chronic group | 20.96 ± 6.70 | 14.00 ± 3.67 | 28.75 ± 4.17 | 65.62 ± 13.26 | 46.68 ± 7.55 | 35.87 ± 7.36 |
| Acute group | 34.44 ± 10.45 | 24.55 ± 7.0 | 65.17 ± 11.09 | 127.90 ± 26.57 | 77.88 ± 9.61 | 70.90 ± 11.95 |
| F | 95.541 | 132.171 | 524.000 | 285.085 | 384.673 | 340.340 |
P < 0.05, Acute group vs Chronic group, the differences are statistically significant.
P < 0.05, Acute group vs Control group, the differences are statistically significant.
LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor-κB; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ.